ResearcherWayne State UniversityNo recent work listed
Anteneh A. Tesfaye
Matched on ORCID iD 0000-0002-7518-1825; OpenAlex author ID A5043399313. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 20
2018: 1 paper · 2019: 4 papers · 2020: 2 papers
Papers 7
- Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-19-1728↗
- Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferation and Patient-Derived Tumor Growth. Co-author DOI 10.3390/cancers12030750↗
- miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.ajpath.2018.10.005↗
- A Pilot Trial of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1089/pancan.2019.0003↗
- Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma With the Introduction of New Chemotherapeutic Drugs: 10-Year Experience of a Single NCI-designat… Co-author DOI 10.1097/coc.0000000000000507↗
- Adjuvant treatment of surgically resectable pancreatic ductal adenocarcinoma. Co-author PMID 30843899↗
- The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. Co-author DOI 10.1080/14737140.2018.1417844↗
Closest collaborators
The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Philip A. Philip · 6 shared papers, 2018–2020 · strength 0.78
- Paper Adjuvant treatment of surgically resectable pancreatic ductal adenocarcinoma. PMID 30843899↗
- Paper miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.ajpath.2018.10.005↗
- Paper The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. DOI 10.1080/14737140.2018.1417844↗
- Asfar Sohail Azmi · 4 shared papers, 2018–2020 · strength 0.47
- Paper miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.ajpath.2018.10.005↗
- Paper The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. DOI 10.1080/14737140.2018.1417844↗
- Paper Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of P… DOI 10.1158/1078-0432.ccr-19-1728↗
- Mandana Kamgar · 3 shared papers, 2018–2020 · strength 0.31
- Paper The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. DOI 10.1080/14737140.2018.1417844↗
- Paper Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of P… DOI 10.1158/1078-0432.ccr-19-1728↗
- Paper Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferat… DOI 10.3390/cancers12030750↗
- Steve H. Kim · 2 shared papers, 2020 · strength 0.19
- Paper Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of P… DOI 10.1158/1078-0432.ccr-19-1728↗
- Paper Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferat… DOI 10.3390/cancers12030750↗
- Mohammed Najeeb Al Hallak · 2 shared papers, 2020 · strength 0.19
- Paper Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of P… DOI 10.1158/1078-0432.ccr-19-1728↗
- Paper Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferat… DOI 10.3390/cancers12030750↗
- Husain Yar Khan · 2 shared papers, 2020 · strength 0.19
- Paper Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of P… DOI 10.1158/1078-0432.ccr-19-1728↗
- Paper Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferat… DOI 10.3390/cancers12030750↗
- Amro Aboukameel · 2 shared papers, 2020 · strength 0.19
- Paper Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of P… DOI 10.1158/1078-0432.ccr-19-1728↗
- Paper Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferat… DOI 10.3390/cancers12030750↗
- Ramzi M. Mohammad · 2 shared papers, 2020 · strength 0.19
- Paper Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of P… DOI 10.1158/1078-0432.ccr-19-1728↗
- Paper Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferat… DOI 10.3390/cancers12030750↗
- Kevin Juan Zhang · 1 shared paper, 2019 · strength 0.11
- Anthony Frank Shields · 1 shared paper, 2019 · strength 0.11
- Irfana Muqbil · 1 shared paper, 2020 · strength 0.09
- Rachel E. Sexton · 1 shared paper, 2020 · strength 0.09
- Maria Diab · 1 shared paper, 2020 · strength 0.09
- Amit Mahipal · 1 shared paper, 2020 · strength 0.09
- Marion L. Hartley · 1 shared paper, 2019 · strength 0.09
- Aiwu Ruth He · 1 shared paper, 2019 · strength 0.09
- Jonathan Robert Brody · 1 shared paper, 2019 · strength 0.09
- Louis M. Weiner · 1 shared paper, 2019 · strength 0.09
- John Lindsay Marshall · 1 shared paper, 2019 · strength 0.09
- Michael Jon Pishvaian · 1 shared paper, 2019 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.